SCHEMBL1726055

SCHEMBL1726055

O=C1NC(=O)C2(Cc3ccc(C(=O)O)cc3C2)N1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALCRL Q16602 6/20 0.44
ALDH1A1 P00352 2/20 0.44
TDP2 O95551 2/20 0.43
CRBN Q96SW2 3/20 0.43
DDB1 Q16531 1/20 0.41
PDE5A O76074 2/20 0.41
PDE1A P54750 2/20 0.41
PDE1B Q01064 2/20 0.41
PDE4D Q08499 2/20 0.41
PDE7A Q13946 2/20 0.41
PDE1C Q14123 2/20 0.41
PDE3A Q14432 2/20 0.41
SRD5A2 P31213 1/20 0.40
KDM4E B2RXH2 3/20 0.39
MAPT P10636 3/20 0.39
POLB P06746 1/20 0.39
BLM P54132 1/20 0.39
GRM1 Q13255 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12698577 1.00 CALCRL (0.44) CALCRLALDH1A1TDP2CRBNDDB1
SCHEMBL14536525 0.90 ALDH1A1 (0.47) CALCRLALDH1A1TDP2CRBNDDB1
SCHEMBL4957736 0.90 ALDH1A1 (0.47) CALCRLALDH1A1TDP2CRBNDDB1
SCHEMBL1714998 0.90 ALDH1A1 (0.47) CALCRLALDH1A1TDP2CRBNDDB1
SCHEMBL12660698 0.87 CALCRL (0.45) CALCRLTDP2CRBNDDB1PDE5A
SCHEMBL14614757 0.87 CALCRL (0.47) CALCRLCRBNDDB1MAPT
SCHEMBL12622666 0.83 CALCRL (0.43) CALCRLCRBNDDB1
SCHEMBL12655217 0.83 CALCRL (0.45) CALCRLALDH1A1CRBNDDB1MAPT
SCHEMBL16659358 0.82 ALDH1A1 (0.53) CALCRLALDH1A1TDP2CRBNDDB1
SCHEMBL13055192 0.78 CALCRL (0.44) CALCRLALDH1A1PDE7APDE3AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1912653-B1 HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2014-01-01 EP disclosed
EP-1912653-B1 HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2014-01-01 EP disclosed
WO-2012129014-A1 PIPERIDINE CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2012-09-27 WO disclosed
WO-2011070283-A8 METHOD AND APPARATUS FOR COOLING AND/OR DEEP-FREEZING MATERIALS IMPLEMENTING THE INJECTION OF TWO CRYOGENIC LIQUIDS L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude (FR) 2012-05-10 WO disclosed
EP-1613368-B1 CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2011-11-30 EP disclosed
EP-1613368-B1 CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2011-11-30 EP disclosed
US-7947678-B2 Heterocyclic benzodiazepine CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-05-24 US disclosed
US-7947678-B2 Heterocyclic benzodiazepine CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-05-24 US disclosed
US-7947678-B2 Heterocyclic benzodiazepine CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-05-24 US disclosed
EP-1606286-B1 BENODIAZEPINE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2011-05-11 EP disclosed
US-20070111982-A1 Calcitonin Gene-Related Peptide, CGRP; treatment of migraine and cluster headache; 2,5-dioxo-3',4'-dihydro-spiro(imidazolidine-4,2'(1'H)-naphthalene)-6'-carboxamides MERCK SHARP & DOHME LLC 2007-05-17 US disclosed
US-20070111982-A1 Calcitonin Gene-Related Peptide, CGRP; treatment of migraine and cluster headache; 2,5-dioxo-3',4'-dihydro-spiro(imidazolidine-4,2'(1'H)-naphthalene)-6'-carboxamides MERCK SHARP & DOHME LLC 2007-05-17 US disclosed
US-20070111982-A1 Calcitonin Gene-Related Peptide, CGRP; treatment of migraine and cluster headache; 2,5-dioxo-3',4'-dihydro-spiro(imidazolidine-4,2'(1'H)-naphthalene)-6'-carboxamides MERCK SHARP & DOHME LLC 2007-05-17 US disclosed
US-7205293-B2 Benodiazepine spirohydantoin CGRP receptor antagonists MERCK & CO., INC. (US) 2007-04-17 US disclosed
US-7205293-B2 Benodiazepine spirohydantoin CGRP receptor antagonists MERCK & CO., INC. (US) 2007-04-17 US disclosed
US-7205293-B2 Benodiazepine spirohydantoin CGRP receptor antagonists MERCK & CO., INC. (US) 2007-04-17 US disclosed
WO-2007016087-A2 HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2007-02-08 WO disclosed
US-20060189600-A1 Benodiazepine spirohydantoin cgrp receptor antagonists MERCK SHARP & DOHME LLC 2006-08-24 US disclosed
EP-1606286-A2 BENODIAZEPINE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2005-12-21 EP disclosed
WO-2004087649-A2 BENODIAZEPINE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189600-A1 Benodiazepine spirohydantoin cgrp receptor antagonists BDKRB2, BDKRB1, CNR2 CALCRL 7/4885ALDH1A1 1317/4885TDP2 2954/4885
US-20070111982-A1 Calcitonin Gene-Related Peptide, CGRP; treatment of migraine and cluster headache; 2,5-dioxo-3',4'-dihydro-spiro(imidazolidine-4,2'(1'H)-naphthalene)-6'-carboxamides CALCA, CALCRL, CALCB CALCRL 2/4885ALDH1A1 2496/4885TDP2 2582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.